Astellas and seagen announce initial results of padcev® (enfortumab vedotin-ejfv) in patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy

Tokyo and bothell, wash., feb. 14, 2022 /prnewswire/ -- astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d.

SGEN Ratings Summary

SGEN Quant Ranking